LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Kodu・Aktsiate loetelu・Veru Inc

Veru Inc

Suletud

0.51

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.5

Max

0.52

Põhinäitajad
By Trading Economics
Sissetulek	1M -7.9M
Aktsiakasum	-0.06
Kasumimarginaal	-128.154
Töötajad	210
EBITDA	2.1M -8.1M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. aug 2025

Turustatistika
By TradingEconomics
Turukapital	1.1M 76M
Eelmine avamishind	0.51
Eelmine sulgemishind	0.51

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

0.5101 / 0.5239 Toetus ja vastupanu

Veru Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. mai 2025, 22:52 UTC

Tulu

Suurimad hinnamuutused turgudel

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15. mai 2025, 20:37 UTC

Peamised uudised

Tulu

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16. mai 2025, 00:00 UTC

Market Talk

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15. mai 2025, 23:47 UTC

Market Talk

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15. mai 2025, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. mai 2025, 23:38 UTC

Market Talk

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15. mai 2025, 23:14 UTC

Peamised uudised

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15. mai 2025, 22:46 UTC

Peamised uudised

Omandamised, ülevõtmised, äriostud

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15. mai 2025, 22:46 UTC

Omandamised, ülevõtmised, äriostud

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15. mai 2025, 22:46 UTC

Omandamised, ülevõtmised, äriostud

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15. mai 2025, 22:46 UTC

Omandamised, ülevõtmised, äriostud

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15. mai 2025, 21:58 UTC

Tulu

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15. mai 2025, 21:24 UTC

Tulu

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15. mai 2025, 20:56 UTC

Market Talk

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15. mai 2025, 20:54 UTC

Market Talk

Tulu

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15. mai 2025, 20:54 UTC

Tulu

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15. mai 2025, 20:51 UTC

Tulu

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15. mai 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15. mai 2025, 20:50 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15. mai 2025, 20:50 UTC

Tulu

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15. mai 2025, 20:47 UTC

Tulu

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15. mai 2025, 20:47 UTC

Tulu

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15. mai 2025, 20:47 UTC

Tulu

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15. mai 2025, 20:47 UTC

Tulu

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15. mai 2025, 20:37 UTC

Tulu

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15. mai 2025, 20:37 UTC

Tulu

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15. mai 2025, 20:37 UTC

Tulu

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15. mai 2025, 20:37 UTC

Tulu

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15. mai 2025, 20:26 UTC

Peamised uudised

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15. mai 2025, 20:25 UTC

Tulu

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Veru Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Veru Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.5101 / 0.5239Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Veru Inc

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.